A continuous-time hidden Markov model for cancer surveillance using serum biomarkers with application to hepatocellular carcinoma
METRON · 2019-08 · 77 (2) · 67-86
DOI: 10.1007/s40300-019-00151-8 ↗Kurz gefasst
Fachartikel in der Zeitschrift METRON, online erschienen am 30.05.2019. Verfasst von Ruben Amoros und 5 weiteren Autor:innen. Beteiligte Einrichtung: 1School of Mathematics, University of Edinburgh, Edinburgh, EH9 3FD UK. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Cancer Research UK, Chief Scientist Office, Scottish Liver Transplant Unit.
Abstract (Originalsprache)
Hepatocellular carcinoma (HCC) is the fourth most common cause of cancer deaths worldwide, and its early detection is a critical determinant of whether curative treatment is achievable. Early stage HCC is typically asymptomatic. Thus, screening programmes are used for cancer detection in patients at risk of tumour development. Radiological screening methods are limited by imperfect data, cost and associated risks, and additionally are unable to detect lesions until they have grown to a certain size. Therefore, some screening programmes use additional blood/serum biomarkers to help identify individuals in whom to target diagnostic cancer investigations. The GALAD score, combining the levels of several blood biomarkers, age and sex, has been developed to identify patients with early HCC. Here we propose a Bayesian hierarchical model for an individual's longitudinal GALAD scores whilst in HCC surveillance to identify potentially significant changes in the trend of the GALAD score, indicating the development of HCC, aiming to improve early detection compared to standard methods. An absorbent two-state continuous-time hidden Markov model is developed for the individual level longitudinal data where the states correspond to the presence/absence of HCC. The model is additionally informed by the information on the diagnosis by standard clinical practice, taking into account that HCC can be present before the actual diagnosis so that there may be false negatives within the diagnosis data. We fit the model to a Japanese cohort of patients undergoing HCC surveillance and show that the detection capability of this proposal is greater than using a fixed cut-point.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- 1School of Mathematics, University of Edinburgh, Edinburgh, EH9 3FD UK.
- 2Department of Gastroenterology, Ogaki Municipal Hospital, Ogaki, Japan.
- 3Institute of Translational Medicine, University of Liverpool, Liverpool, UK.
- 4Cancer Research UK Beatson Institute, Switchback Road, Glasgow, G61 1BD UK.
- 5MRC Centre for Inflammation Research, The Queens Medical Research Institute, University of Edinburgh, Edinburgh, EH16 4TJ UK.
ORCID-Profile: Ruben Amoros
Förderung
- Cancer Research UK
- Chief Scientist Office
- Scottish Liver Transplant Unit
- Wellcome Trust
Zitieren
APA
Amoros, R., King, R., Toyoda, H., Kumada, T., Johnson, P. J., & Bird, T. G. (2019). A continuous-time hidden Markov model for cancer surveillance using serum biomarkers with application to hepatocellular carcinoma. METRON, 77(2), 67-86. https://doi.org/10.1007/s40300-019-00151-8
Vancouver
Amoros R, King R, Toyoda H, Kumada T, Johnson PJ, Bird TG. A continuous-time hidden Markov model for cancer surveillance using serum biomarkers with application to hepatocellular carcinoma. METRON. 2019;77(2):67-86. doi:10.1007/s40300-019-00151-8
BibTeX
@article{Amoros2019,
author = {Amoros, Ruben and King, Ruth and Toyoda, Hidenori and Kumada, Takashi and Johnson, Philip J and Bird, Thomas G},
title = {A continuous-time hidden Markov model for cancer surveillance using serum biomarkers with application to hepatocellular carcinoma},
journal = {METRON},
year = {2019},
volume = {77},
number = {2},
pages = {67--86},
doi = {10.1007/s40300-019-00151-8}
}
EUVIMED